PUTTING WORKERS FIRST?

Who are the Trump Administration & Congress (really) fighting for?
"Every decision . . . will be made to benefit American workers."
- President Trump, Inaugural Address, Jan 20, 2017
View By Week
View By Month
Browse by topic
Accountability Agriculture Airline Apprenticeships Arbitration Automotive Benefits Border Wall Boycotts Budget Census CFPB China CMS Coal commerce Conflict of Interest Congress Construction contractors Corporate Defense DHHS Disability Benefits Disabled Workers Discrimination DOD DOE DOJ DOL Dreamers Education Employment Energy EPA Equal Opportunity Executive Executive Order Farmers Fast-Food Federal Aid Federal Contract Employees Federal Contractors Federal Workforce Fiduciary Rule Fortune 100 General Gig Economy Gig Workers Health & Safety Health and Safety Health Care HHS Home Care Housing HUD Immigrant Workers Immigration Infrastructure IRS Janitorial Jobs Joint Employer Judicial Justice Labor Legislation Legislative Low-Income Maintenance Manufacturing Meatpacking Military Minimum Wage Misclassification Muslim NLRB Nominations Offshore OPM OSHA Overtime Parks and Recreation Persuader Rule Pharma Plant Workers Poultry Public-Sector Reg Regulatory Religion Retirement Retirement Savers Same-sex Social Security Steel Workers Student Loans Students Subcontracting Supreme Court Tariff Taxes Temp-workers Tip Theft Tipped Workers Tips Trade Transgender Transportation Treasury Unemployed Unemployment Insurance Unions USDA USTR Wage and Hour Wage-theft White House Youth Workers
Week 97
Nov 30, 2018

DOJ informs the Supreme Court it plans to dismiss drug contamination cases against Gilead despite siding with whistleblowers.

  • DOJ tells the Supreme Court that a whistleblower's FCA suit filed against Gilead for concealing an illegal drug supplier and contamination won't go forward if the Supreme Court remands it because it is too burdensome on the FDA to fulfill discovery requests and not in the public interest.
  • This dismissal would be a blow to whistleblowers, and pose a huge risk to consumers of drugs involved in the case, such as Atripla, Truvada and Emtriva and it could set a dangerous precedent of government interference in the name of the "public interest".
Read More
DOJ, Health and Safety, Judicial, Pharma, Supreme Court
Explore Our Library
Publications Explore Our Library
Meet Our Experts
Experts Meet Our Experts
Visit the Newsroom
Newsroom Visit the Newsroom
Contact

National Employment Law Project

90 Broad Street, Suite 1100, New York, NY 10004

Photography Credits

U.S. Department of Labor

Work With Us

View Job Openings

Follow us
General Inquiries

nelp@nelp.org
Subscribe
The site is for informational purposes only and does not provide legal advice. Website by Briteweb
Back to Top of Page